Biohaven Ltd. (NYSE:BHVN) CEO Acquires $4,999,991.00 in Stock

Biohaven Ltd. (NYSE:BHVN) CEO Vlad Coric bought 121,951 shares of the stock in a transaction that occurred on Monday, April 22nd. The shares were purchased at an average cost of $41.00 per share, with a total value of $4,999,991.00. Following the purchase, the chief executive officer now directly owns 1,788,417 shares of the company’s stock, valued at $73,325,097. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Biohaven Price Performance

Shares of NYSE BHVN opened at $39.60 on Wednesday. The stock has a market capitalization of $3.24 billion, a P/E ratio of -7.00 and a beta of 1.18. The company has a 50-day moving average price of $51.63 and a 200-day moving average price of $41.70. Biohaven Ltd. has a 1 year low of $12.35 and a 1 year high of $62.21.

Biohaven (NYSE:BHVN) last issued its quarterly earnings data on Thursday, February 29th. The company reported ($1.81) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.41) by ($0.40). As a group, equities research analysts anticipate that Biohaven Ltd. will post -5.85 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Simon Quick Advisors LLC grew its holdings in shares of Biohaven by 36.3% during the fourth quarter. Simon Quick Advisors LLC now owns 74,968 shares of the company’s stock valued at $3,209,000 after buying an additional 19,968 shares during the last quarter. Citigroup Inc. boosted its holdings in Biohaven by 97.9% during the third quarter. Citigroup Inc. now owns 146,907 shares of the company’s stock worth $3,821,000 after purchasing an additional 72,673 shares during the last quarter. Legato Capital Management LLC purchased a new position in Biohaven during the fourth quarter worth about $469,000. Monashee Investment Management LLC boosted its holdings in Biohaven by 80.0% during the third quarter. Monashee Investment Management LLC now owns 90,000 shares of the company’s stock worth $2,341,000 after purchasing an additional 40,000 shares during the last quarter. Finally, GSA Capital Partners LLP purchased a new position in Biohaven during the third quarter worth about $923,000. 88.78% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages recently weighed in on BHVN. JPMorgan Chase & Co. lifted their target price on shares of Biohaven from $32.00 to $56.00 and gave the stock an “overweight” rating in a research note on Friday, February 23rd. HC Wainwright raised their price target on shares of Biohaven from $50.00 to $63.00 and gave the stock a “buy” rating in a report on Monday, March 4th. TD Cowen raised their price target on shares of Biohaven from $35.00 to $55.00 and gave the stock an “outperform” rating in a report on Friday, March 1st. Royal Bank of Canada restated an “outperform” rating and issued a $61.00 price target on shares of Biohaven in a report on Tuesday, April 9th. Finally, UBS Group raised their price target on shares of Biohaven from $59.00 to $60.00 and gave the stock a “buy” rating in a report on Tuesday. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Biohaven has a consensus rating of “Buy” and a consensus price target of $52.13.

About Biohaven

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.